[{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Yumanity Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.5,"dosageForm":"","sponsorNew":"Yumanity Therapeutics \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Yumanity Therapeutics \/ Merck"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KCP506","moa":"nAchR","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Proteostasis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Yumanity Therapeutics \/ Proteostasis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Proteostasis Therapeutics"},{"orgOrder":0,"company":"Kineta","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"KCP-506","moa":"nAchR","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Genentech"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anti-VISTA antibodies","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Human anti-VISTA antibodies","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anti-VISTA antibodies","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Proteostasis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Yumanity Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Yumanity Therapeutics"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"LHF-535","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Kineta \/ Wellcome Trust","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Wellcome Trust"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Cheongbo Industrial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kineta \/ Cheongbo Industrial","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Cheongbo Industrial"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"VISTA","moa":"Checkpoint","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Kineta","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Kineta"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Humedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Kineta"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Alpha CD27 mab","moa":"Anti-CD27","graph1":"Oncology","graph2":"Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Anti-CD27 Monoclonal Antibody","moa":"Anti-CD27","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Kineta","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Merger","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Kineta"},{"orgOrder":0,"company":"Kineta","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Merck"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CD27","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Merger","leadProduct":"KVA12123","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Yumanity Therapeutics \/ Yumanity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Yumanity Therapeutics \/ Yumanity Therapeutics"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Private Placement","leadProduct":"KVA12123","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Kineta","amount2":0.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.5,"dosageForm":"","sponsorNew":"Kineta \/ Merck & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Kineta","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"KVA12123","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Kineta","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kineta","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kineta \/ TuHURA Biosciences","highestDevelopmentStatusID":"14","companyTruncated":"Kineta \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"KVA12123","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kineta \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Yumanity Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KVA12123 is a VISTA inhibitor antibody, It is being evaluated in combination with keytruda for the treatment of patients with neoplasms including lung cancers.

                          Brand Name : KVA12123

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 08, 2024

                          Lead Product(s) : KVA12123,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KVA12123 is a novel VISTA blocking monoclonal antibody being evaluated in a Phase 1/Phase 2 clinical trial for patients with advanced solid tumors.

                          Brand Name : KVA12123

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 02, 2024

                          Lead Product(s) : KVA12123,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : TuHURA Biosciences

                          Deal Size : $5.0 million

                          Deal Type : Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KVA12123 is a VISTA inhibitor antibody, It is being evaluated in combination with keytruda for the treatment of patients with neoplasms including lung cancers.

                          Brand Name : KVA12123

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 19, 2024

                          Lead Product(s) : KVA12123,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KVA12123, VISTA inhibitor, in combination with Keytruda. Currently, it is being evaluated in the Phase III clinical trial studies for the treatment of neoplasms including Lung Cancer.

                          Brand Name : KVA12123

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 12, 2024

                          Lead Product(s) : KVA12123,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KVA12123 is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. It is under phase 1/2 clinical development for advanced solid tumors.

                          Brand Name : KVA12123

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          January 17, 2024

                          Lead Product(s) : KVA12123

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KVA12123 is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment, which is being investigated in combination with pembrolizumab in patients with advanced solid tumors.

                          Brand Name : KVA12123

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 17, 2023

                          Lead Product(s) : KVA12123,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KVA12123 is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a uniqu...

                          Brand Name : KVA12123

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 03, 2023

                          Lead Product(s) : KVA12123,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The agreement aims to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.

                          Brand Name : KVA12123

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 18, 2023

                          Lead Product(s) : KVA12123,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Fred Hutchinson Cancer Center

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration is focused on the discovery and development of two novel Yumanity pipeline programs for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 29, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Merck & Co

                          Deal Size : $500.0 million

                          Deal Type : Collaboration

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KVA12123 is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a uniqu...

                          Brand Name : KVA12123

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 12, 2023

                          Lead Product(s) : KVA12123,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank